CTLA-4 antibody ipilimumab negatively affects CD4⁺ T-cell responses in vitro.

ABSTRACT: Immune checkpoint inhibitors targeting coinhibitory pathways in T cells possess efficacy in combating cancer. In addition to PD-1/PD-L1 and CTLA-4 antibodies which are already established in tumor immunotherapy, immune checkpoints such as LAG-3 or BTLA are emerging, which may have the potential to enhance T-cell responses alone or in combination with PD-1 blockers. CD4⁺ T cells play a central role in the immune system and contribute to productive immune responses in multiple ways. The effects of immune checkpoint inhibitors on this cell subset may thus critically influence therapeutic outcomes. Here, we have used in vitro responses to tetanus toxoid (TT) as a model system to study the effects of immune checkpoint inhibitors on CD4⁺ T-cell responses. CFSE-labeled PBMCs

SUBMITTER: Rosskopf S 

PROVIDER: S-EPMC6683241 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature